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Abstract. The present study aimed to evaluate the role 
of adjuvant radiotherapy (RT) following nipple-sparing 
mastectomy (NSM) for patients with ductal carcinoma 
in situ and invasive breast cancer, based on the published 
literature. Currently, there is no standard for RT following 
NSM. NSM aims to spare the nipple areola complex (NAC) 
without compromising locoregional control. Long-term 
follow-up studies have begun to show promising results. 
A search of the English literature was performed using the 
Medline database and Cochrane central library, with the 
keywords ‘nipple/areola-sparing mastectomy’, ‘whole skin 
mastectomy’ and ‘NAC preservation’. A total of 32 original 
studies with data on NSM in terms of locoregional control, 
NAC control, NAC necrosis and adjuvant RT were identi-
fied. The median locoregional and NAC recurrence rates 
were 3.2 and 1.4% (range, 0-28.4% and 0-3.7%), respectively. 
The volume of remaining breast tissue following NSM was 
reported inconsistently. In 15 studies, RT was not mentioned. 
In the remaining 17 studies, RT was administered in 0-100% 
of patients. Only 7 studies provided detailed information 
regarding the use of adjuvant RT. Adjuvant thoracic wall 
irradiation was not used in certain studies, not even for 
locoregionally advanced tumors. Overall, NSM appears a 
feasible treatment without increased risk of locoregional 
recurrence for selected patients. The role of adjuvant RT 
following NSM requires further clarification. The decision 
regarding adjuvant RT must be made in interdisciplinary 
tumor boards and with consideration of the individual situ-
ation of the patient.
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1. Introduction
Breast-conserving therapy (BCT) is the gold standard for the 
majority of patients with localized breast cancers. In ~25% of 
breast cancer patients, a mastectomy is indicated for multi-centric 
or large tumors, and for local recurrence following BCT (1). 
Radical mastectomy is disfiguring, with removal of all the skin, 
the sub-mammarial fold and the nipple-areola complex (NAC). 
As a consequence, skin-sparing techniques have been intro-
duced and demonstrated to provide similar outcomes compared 
with radical mastectomy (2). A study by Gerber et al (3) was 
the first to describe nipple‑sparing mastectomy (NSM), which 
additionally saved the NAC, aiming to improve the esthetics 
and psychological results. The indications of NSM have been 
extended from a prophylactic scenario and small tumors distant 
from the NAC to larger and multi-centric tumors (4,5). There 
are several studies and reviews on NSM (1,2,5-10), a number 
of which focus on oncological safety (3,11-24), cosmetic 
outcome (24-29) and surgical techniques (24-32). The role 
of adjuvant radiotherapy (RT), including dose-fractionation 
concepts and techniques (6), remains unclear.
This review focuses on the use of adjuvant therapy 
following NSM to further clarify its role in the setting of this 
surgical technique.
2. Database search
A systematic review of the English literature was carried out 
using the Medline database and Cochrane Central Library. 
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Keywords were ‘nipple/areola-sparing mastectomy’, ‘whole skin 
mastectomy’, ‘NAC preservation’ and ‘adjuvant radiotherapy’. 
Each study presenting data on nipple-sparing mastectomy in 
ductal carcinoma in situ (DCIS) or breast cancer patients was 
reviewed focusing on the use of adjuvant RT. In addition, data 
on locoregional control, NAC control and NAC necrosis were 
collected. Studies reporting exclusively on prophylactic NSM 
and studies with <10 patients were excluded. The majority of 
study groups reported on NSM in a prophylactic setting and 
NSM for invasive cancer, however, the present review was 
limited to data from patients with DCIS and invasive breast 
cancer, as RT is not used in the prophylactic setting.
3. Indications of NSM
A total of 32 original studies concerning NSM in patients with 
DCIS and/or invasive cancer were identified. In 11 studies, the 
inclusion criterion for NSM was small tumors >1-2 cm distant 
from the NAC (1,33). In 21 studies, locally advanced and 
multi-centric tumors were included (4,34,35). Only 5 studies 
excluded T3/4 tumors and patients with ≥4 positive lymph 
nodes. Recent data has shown an increasing use of NSM in 
the more advanced disease stages (4,34). It is generally agreed 
that involvement of the skin/NAC (1), inflammatory tumors (2) 
and Paget's disease (3) are contraindications for NSM. Unde-
tected tumor involvement of the clinically non-involved NAC 
is a critical point. In a previous study, the rate of histopatho-
logical NAC involvement in patients treated with NSM ranged 
between 0 and 58% (6). Risk factors for involvement are tumor 
location, number of positive lymph nodes and lymphovascular 
invasion (36). Tumor size and distance from the NAC, as 
measured by magnetic resonance imaging, are correlated with 
an increased risk of NAC involvement (37). Almost all studies 
identified used intraoperative pathological assessment (frozen 
sections) of the subareolar tissue for deciding whether NSM 
could be carried out or not. In cases of involvement of the 
NAC, the complex was not spared (25,29,33).
4. Oncological outcome and complications
The number of patients included in the identified studies ranged 
from 26 to 1,001 patients (median, 147 patients), and the follow-up 
period ranged from 10 to 156 months (median, 38.4 months). The 
data for these studies is summarized in Table I. In total, 8 studies 
provided follow-up data for 5 years or longer. The majority of the 
studies focused on oncological feasibility (locoregional control), 
safety and cosmetic outcomes. Locoregional recurrence in the 
treated breast occurred in 0-28.4% of cases (median, 3.2% of cases) 
and recurrence in the NAC in 0-3.7% of cases (median, 1.4% of 
cases). The rate of total NAC necrosis and partial NAC necrosis 
ranged from 0-10% and 0-28.2%, with median values of 4.4 and 
6.8%, respectively. Only one study addressed the potential impact 
of post-operative radiation on NAC necrosis: Carlson et al 
observed no difference in nipple necrosis with (n=9) or without 
(n=36) the application of RT (32).
5. Adjuvant RT
In 15 studies, the administration of adjuvant RT was not 
mentioned. A total of 10 studies reported the percentage of 
patients treated with adjuvant RT without providing more 
details with respect to indication, technique and prescribed 
doses, while 7 studies described at least the indication for 
adjuvant RT. In total, RT was administered in 6 to 100% of 
patients according to 17 analyses. 
Sakurai et al reported a study of 788 patients without adjuvant 
RT following NSM in Union for International Cancer Control 
stage 0-IV patients (38). The locoregional recurrence rate of 
8.2% and the NAC recurrence rate of 3.7% were comparable 
to the rates of other studies (Table 1) (3,4,12-36,38-40,47,49).
Burdge et al (34) and Boneti et al (25) delivered 50 Gy 
to the thoracic wall (with or without lymphatic drainage) for 
tumors >5 cm and/or in cases with ≥4 positive lymph nodes. 
Moyer et al applied RT for resection margins ≤1 mm (28). In 
another study, the application of 50 Gy to the thoracic wall 
depended only on the treating physician's decision (proportion 
of irradiated patients not mentioned) (13).
Petit et al (42) performed RT exclusively to the NAC as 
either electron intraoperative RT (ELIOT; Fig. 1) (42) or as a 
single dose of 16 Gy (electron beams) a few days after surgery. 
The study reported a rate of locoregional recurrence of 1.4%, 
with all recurrences distant from the NAC. The outcomes 
were not significantly different between the patients receiving 
ELIOT (n=800) and those receiving delayed post-operative 
RT (n=201) (29). In six other studies providing statements on 
RT, a dose of 50 Gy was applied to the thoracic wall using 
conventional fractionation, with daily doses of 2 Gy admin-
istered on 5 days per week (13,14,18,25,28,34). In the study 
by Rulli et al, the decision for adjuvant RT was based on the 
remaining breast tissue, with residual glandular tissue as an 
indication for RT (n=10) and no remaining tissue after NSM as 
an indication for withholding RT (n=50) (18). Only one study 
group found a significant difference in locoregional recurrence 
rate depending on the application of RT, as determined in 
216 patients (8.5% with RT vs. 28.4% without RT) (12). The 
tumor stage contributions in the two groups were not supplied. 
No observations of a higher rate of NAC necrosis following the 
application of adjuvant RT were reported.
No study was found commenting on the radiation boost 
volume, including the NAC area.
Figure 1. Electron intraoperative radiotherapy. a, sterile collimator of the 
linear accelerator; b, gauze over areola; c, protective lead; d, pectoralis 
major muscle. Figure reproduced from Petit et al (42) with permission.
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6. Cosmesis
Djohan et al (26) demonstrated high patient satisfaction 
rates with the appearance of the NAC following NSM, as 
determined by self-assessment and assessment by indepen-
dent observers in a cohort of 141 patients, with a median 
follow‑up period of 8 years. Other studies confirmed these 
good cosmetic outcomes (25,27,28). Petit et al (29) achieved 
a global result of 8/10, as rated by patients and surgeons, 
respectively, following ELIOT. Radiodystrophy, such as 
teleangiectasia, have been observed in 5.1% of 898 cases (39). 
None of the study groups reported an impaired cosmetic 
outcome following the addition of adjuvant RT.
7. Disease control
According to the reviewed literature, NSM appears a 
feasible option without an increased risk of locoregional 
recurrences for selected patients with invasive breast cancer 
and/or DCIS (12-16,19-24,39,40). Including a wide range of 
tumor (T) and node (N) stages, and tumor distances from the 
NAC, the overall NAC recurrence rates were low, ranging 
from 0-3.7% (Table I).
8. Complications
As the majority of studies removed all breast tissue under 
the NAC, necrosis due to compromised blood supply is a 
significant complication to consider. Algaithy et al (41) and 
Gould et al (43) found a positive correlation between a higher 
rate of NAC necrosis and smoking history, type of incision, 
body mass index and hypertension/diabetes mellitus. The 
wide variation in percentage of NAC necrosis (0-28.2%) 
could be explained by the lack of a standardized surgical 
technique (6).
None of the studies describing adjuvant RT revealed 
increased rates of partial or complete NAC necrosis 
following adjuvant RT. Only the study by Burdge et al (34), 
in which high-risk patients were treated with NSM and an 
adjuvant RT dose of 50 Gy to the thoracic wall, recorded 
complication rates following adjuvant RT. The study divided 
the complications into non-breast-related (6.7%), such as 
radiation pneumonitis, and breast-related (30.8%) complica-
tions. The study concluded NSM to be feasible in patients 
requiring adjuvant RT, with complication rates similar to 
those following conventional mastectomy. In order to avoid 
increased complication rates a delayed reconstruction was 
suggested following completion of RT (34). 
9. NSM and adjuvant RT
Of the 32 studies with primary data on NSM in DCIS and/or 
invasive breast cancer included in the present review, only 
7 provided detailed information on adjuvant RT, while 
15 studies did not mention the use of RT following NSM. 
Therefore, it remains unclear if RT was administered but 
not mentioned or more likely, not administered at all. The 
majority of studies used conventionally fractionated RT 
to the thoracic wall (and lymphatic drainage) in high-risk 
groups with tumors >5 cm and/or with ≥4 involved lymph 
nodes or close margins (25,28,34). In the study by Rulli et al, 
RT was only performed in patients with remaining breast 
tissue after surgery (18). The largest contribution to the role 
of RT following NSM has been made by Petit et al (42). The 
study initially described an intraoperative approach with a 
16-Gy dose (electron beams) to the NAC with a margin of 
1 cm around the areola (ELIOT; Fig. 1), which is believed 
to be equivalent to a 40-45-Gy fractionated dose according 
to the linear-quadratic model (10). In 2009, the study group 
reported on a large patient cohort of 1,001 patients treated 
with either ELIOT (n=800) or delayed RT (16-Gy single 
dose a few days post-surgery; n=201) (29). The treatment 
outcomes in terms of locoregional control were similar. 
To the best of our knowledge, the only study showing a 
significant difference in locoregional control based on the 
application of RT following NSM was the study by Bene-
diktsson and Perbeck (17). This may be explained by the fact 
that in every patient a plate of gland tissue (thickness, 5 mm) 
with a 2 cm diameter was left around the NAC. According to 
national guidelines for BCT this would have been an indica-
tion for RT in any case (44-46). No comments were found on 
boost application/boost doses applied to the NAC.
In addition, there are two critical points to consider: 
21 of the identified studies included high‑risk patients with 
≥T3 tumors and/or lymph node involvement of ≥4 posi-
tive lymph nodes, and did not comment on adjuvant 
RT (5,20,21,27,33,38,40,47). For advanced TN stages, several 
recent national guidelines have recommended external beam 
RT to the whole thoracic wall, with or without irradiation of 
the lymphatic drainage system (44-46). A recent review of the 
Early Breast Cancer Trialists' Collaborative Group found that 
after mastectomy and axillary dissection, RT reduced recur-
rence and breast cancer mortality in women with 1-3 positive 
lymph nodes, even when systemic therapy was applied (48).
Petit et al (29) performed intraoperative RT (IORT) using 
a 16-Gy single dose exclusively to the NAC, which is not in 
accordance with the aforementioned most recent guidelines 
for more advanced tumors. In the study, 21% of the patients 
presented with either a T3 tumor or ≥4 positive lymph nodes. 
In 2011, Petit et al (10) stated that conventional post-operative 
RT is usually delivered when patients present with high-risk 
factors. In the Japanese study that completely omitted RT in 
all patients, 12.5% of the patients presented with a stage T3 
or T4 tumor (38).
The second critical point regarding the indication for 
RT in breast cancer patients following NSM is the amount 
of remaining tissue. In certain studies, a thin layer of tissue 
underneath the NAC was preserved, whereas in other 
studies, the NAC was completely removed. In the majority 
of patients, the entire breast tissue below the NAC was 
removed (Table I). Additionally, certain studies did not 
provide a detailed description of the surgical techniques 
used (3,4,9,3,26,28,47). In other studies, the aim was to 
remove as much breast tissue as possible (49), or to leave a 
certain degree of breast tissue beneath the NAC in order to 
ensure the blood supply of the NAC (17,18,29,33). In the latter 
situation, one would argue that adjuvant RT is necessary, as 
the remaining breast tissue is at risk for local recurrence. In 
cases of a T1/2N0 tumor, this could be performed with the 
ELIOT method, in agreement with the recommendations for 
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an alternative use of IORT or accelerated partial breast irra-
diation following breast-conserving therapy (50,51). In cases 
of a more advanced tumors or when IORT is unavailable, 
fractioned RT to the entire chest wall or post-operative single 
dose RT would be required. Petit et al (10) recommended 
RT to the NAC to reduce the risk of a local recurrence 
when breast tissue has been left behind the NAC, and if the 
distance between the tumor and the nipple is small. The 
role of a boost to the NAC is also debatable in patients with 
remaining breast tissue. None of the reviewed studies carried 
out a boost following thoracic wall RT. Omitting of RT after 
NSM may be discussed for low-stage tumors in patients with 
no remaining breast tissue behind the NAC.
10. Conclusion
Several retrospective studies have shown that NSM is a 
feasible option without an increased risk of local recurrences 
in selected patients with invasive breast cancer and/or DCIS. 
The surgical techniques and volume of resected breast tissue 
vary considerably.
Currently, there is no consensus regarding the use of adju-
vant RT following NSM. For patients who meet the criteria 
for adjuvant RT following radical mastectomy (T3/T4, posi-
tive margins and lymph node involvement) adjuvant RT to 
the thoracic wall should be administered. In patients with a 
lower stage tumor, RT to only the NAC may be discussed. 
The decision for or against adjuvant RT following NSM 
requires an interdisciplinary tumor board, taking the benefits 
and potential risks for the individual patient into account.
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